The sequential transcriptional activation of cyclins, the regulatory subunits of cell-cycle-specific kinases, is thought to regulate progress through the cell cycle. Cyclins are therefore potential oncogenes, and cyclin D1 overexpression and/or amplification at its genomic locus, 11q13, are common features of several human cancers. Induction of cyclin D1 is an early response to mitogenic stimulation in several cell types, but the consequences of altered expression of this gene in human cells of epithelial origin remain undefined. We assessd the effects of alterations of cyclin D1 expression in human breast cancer cells by generating T-47D cells expressing human cyclin D1 under the control of a zinc-responsive metallothionein promoter. In cycling cells induction of cyclin D1 after zinc treatment resulted in an increase in the number of cells progressing through G1 and in the rate of transition from G1 to S phase, indicating that cyclin D1 is rate-limiting for progress through G1 phase. In cells arrested in early G1 phase after growth factor deprivation, zinc induction of cyclin D1 was sufficient for completion of the cell cycle, a process requiring growth factor stimulation in control cells. These data demonstrate a critical role for cyclin D1 in human breast cancer cell-cycle control and suggest that deregulated expression of cyclin D1 is likely to reduce dependence on normal physiological growth stimuli, thereby providing a growth advantage to tumor cells and a potential mechanism of resistance to endocrine therapy.
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Cell-cycle progression in mammalian cells is coordinated at a series of control points, which ensure orderly progress through the complex and tightly regulated processes necessary for cell growth and division. The central mechanism for these control points is thought to be the sequential transcriptional activation of cycin genes and consequent transient accumulation of different cyclin/cycin-dependent kinase (CDK) complexes. In synchronized or growth factorstimulated cells, cyclins C, D1, D2, D3, and E are most abundant during G1 phase (1) (2) (3) , suggesting that they function during G1. The D cyclins have closely related sequences but are differentially expressed: some cells express all three genes [for example, mammary epithelial cells (4) ], but many cell types express only one or two (2, 5, 6) . Furthermore, these cyclins are not coordinately regulated but, in general, appear sequentially during progress through G1 phase (2, (6) (7) (8) (9) , suggesting that they have complementary rather than redundant functions.
Regulation of cyclin D1 gene expression is closely associated with changes in the proliferation rate of breast cancer cells. Increased expression of cyclin D1 occurs within 2 hr of stimulation of T-47D breast cancer cells by peptide mitogens-for example, insulin, insulin-like growth factor I, and basic fibroblast growth factor-and is followed by induction of other G1 cyclins, cyclins D3 and E, as cells progress through G1 phase (ref. 8, unpublished data). The proportion of cells that enter S phase is related to the degree of induction of cyclins D1, D3, and E (8). Regulation of cyclin D1 expression also occurs rapidly upon treatment with mitogenic steroids, estrogen, and progestin (ref. 8 , unpublished data) and precedes growth inhibition by antiestrogens (8) . These data suggest that regulation of cyclin D1 expression could contribute to regulation of breast epithelial cell proliferation by some steroids and steroid antagonists.
It has been proposed that G1 cycins are protooncogenes whose inappropriate expression may lead to loss of normal growth control. This hypothesis is supported by several lines of evidence. Aberrant expression of cyclin D1 through chromosomal translocation, gene amplification, and/or overexpression is a common feature of a number of human cancers, including B-cell lymphomas, squamous cell carcinomas of the head and neck, lung, and esophagus, as well as breast and bladder carcinoma (4, 12, 13) . Up to 23% of breast carcinomas display amplification of the chromosomal locus of the cyclin D1 gene, 11q13 (14) (15) (16) , and a greater fraction display increased expression of cyclin D1 mRNA in the presence or absence of gene amplification (4) . The functional consequences of cyclin D1 gene regulation or aberrant expression have yet to be investigated in these cells, but the differential expression and distinct functions of the D-type cyclins suggest that their effects may be tissue-specific.
T-47D human breast cancer cells are representative of a well-differentiated, estrogen receptor-positive breast cancer phenotype, in which 11q13 amplification most commonly occurs (13) , and are growth-regulated by estrogen, progestins, and their antagonists. No evidence for cyclin overexpression or amplification has been found in these cells (4) , and the pattern of cyclin gene expression of T-47D cells after growth factor stimulation is indistinguishable from that of normal mammary epithelial cells (6, 8, 17) , in contrast to aberrant cyclin expression in some other breast cancer cell lines (4, 17) . Therefore, T-47D cells were used to examine the consequences of increased cyclin D1 expression in human breast cancer. These experiments demonstrated that cyclin D1 is not only cell-cycle regulated in these cells but is cell-cycle regulatory, with effects on both the rate ofprogress through G1 phase and the proportion of cells initiating cellcycle progression.
MATERIALS AND METHODS
Cell Lines and Cell Culture. The T-47D cell line from the E. G. and G. Mason Research Institute (Worcester, MA) was cloned by limiting dilution, and one clonal cell line, T-47D (7-2), was selected for transfection studies. T-47D (7-2) retained the characteristics of the parent line by all the criteria tested-i.e., growth rate in stock culture conditions, sensitivity to growth regulation by steroids and steroid antagonists (progestin, ORG 2058; antiestrogen, ICI 164384; and antiprogestin, RU 486), and abundance of cyclin D1 and c-myc mRNA.
RPMI 1640 medium was used throughout. Stock cultures were maintained in medium supplemented with human insu-
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. 8023 lin at 10 pg/ml (CSL-Novo, North Rocks, NSW, Australia) and 10o fetal calf serum. Serum-free medium was phenol red-free and supplemented with 300 nM human transferrin (Sigma) and, where noted, insulin at 10 pug/ml. Cells were cultured in serum-free medium following a described protocol (18, 19) .
Expression Vectors and Transfection Procedures. The inducible expression vector pAMTcycD1 was constructed by cloning human cyclin Dl coding sequences (5) into the Sal I/Acc I site of pAMT (20) . Parallel flasks of T-47D (7-2) cells were cotransfected with 50 pg of pAMTcycD1 or pAMT and 5 pg of pSV2neo, using standard calcium phosphate precipitation methods, and after 3 weeks colonies resistant to G418 at 600 pg/ml were trypsinized and pooled, to yield the T-47D AMTcycD1 and T-47D AMT cell lines. Experiments were done within 11 weeks. DNA fingerprinting using a Pvu II restriction fragment length polymorphism of the mucin gene confirmed that each cell line was a derivative of T-47D.
Analysis of Cell Cycle Progression. Cell-cycle phase distribution was determined by analytical DNA flow cytometry, as described (21) . G1 exit kinetics were measured using a previously published stathmokinetic technique (22, 23) .
RNA Isolation and Northern Blot Analysis. Replicate 150-cm2 flasks of cells were treated with 50 uM ZnSO4 or vehicle, and total RNA was extracted (using a guanidiniumisothiocyanate-cesium chloride procedure), blotted, and hybridized as described (18) . Equivalent RNA loading was verified by hybridization to an oligonucleotide recognizing 18S rRNA sequences (18) .
Cell Extraction and Immuoblot Analysis. Cell lysates from replicate 75-cm2 flasks of cells treated with 10-50 AM ZnSO4 or vehicle were prepared as described (24), except that p-nitrophenyl phosphate was omitted from the lysis buffer. Equal amounts of total protein (typically 30 pg per lane) were separated by SDS/10%o PAGE. Cyclin Dl protein was detected after incubation (2-4 hr at room temperature) with a 1:1000 dilution of a rabbit polyclonal antibody raised against a cyclin DI amino-terminal epitope (Santa Cruz Biotechnology) followed by horseradish peroxidase-linked anti-rabbit antibody (1 hr at room temperature) and visualized using the enhanced chemiluminescence detection system (Amersham).
RESULTS
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Alterations in cylin Dl expression in breast cancer cells were examined by generating T-47D cells expressing cyclin Dl under the control of a metal-inducible truncated human metallothionein IIA promoter lacking steroid-responsive sequences (20) ; these cells were designated T-47D AMTcycD1. Upon zinc treatment the abundance of cyclin Dl mRNA transcripts expressed from the introduced vector increased within 1 hr, reached a maximum at 6 hr, and remained elevated (up to 4-fold) until the last time point examined, 24 hr (Fig. 1A) . Cyclin Dl protein also increased (-5-fold) with zinc treatment of T-47D AMTcycD1 (Fig. 1C) . Zinc treatment of cells transfected with vector alone (T-47D AMT) had little effect on either cyclin DI mRNA or protein abundance ( Fig. 1 B and D) .
The effects of cyclin Dl induction on cell-cycle progression in cycling cells were determined by using T47D AMTcycD1 and T-47D AMT cells cultured in serum-free medium containing insulin as a mitogen. These defined growth conditions result in exponential proliferation at a rate that allows detection of both stimulation and inhibition of proliferation (8, 18) . Major changes in cell-cycle-phase distribution were detected after 24-hr zinc treatment of cells expressing exogenous cyclin D1 (Fig. 2A) . The proportion of S-phase cells increased from Z22% to 57%, and the G2 + M peak also significantly increased (from 9% to 16%). In contrast, the AM resulted in a concentrationdependent increase in relative cyclin D1 protein levels, ranging from <2-fold to a maximum of >7-fold (Fig. 4A) . As expected, cyclin D1 abundance affected the rate of exit from G1 phase, which increased with increased zinc concentration (Fig. 4B) . However, by 21 Duplicate flasks were harvested at intervals thereafter for determination of cell-cycle-phase distribution by flow cytometry. Lines of best fit to data from 4-13.5 hr (control) or 6-13.5 hr (zinc-treated) were calculated by linear-regression analysis.
phase reached a minimum that was also concentrationdependent (Fig. 4B ). These data suggest that not only the rate of progression, but also the proportion of the cell population that initiates progression through G1, depends on cyclin D1 abundance. The cyclin D1 protein abundance 6 hr after zinc treatment correlated with the proportion of cells reaching S phase by 21 hr (Fig. 4C) , supporting this conclusion.
Cyclin D1 Induction Is Sufficient for G1 Transit in Breast Cancer Cells. In serum-free medium lacking exogenous mitogens, T-47D cells are growth-arrested at the beginning of G, phase (19) . Upon addition of a single growth factor-e.g., insulin, insulin-like growth factor I, or basic fibroblast growth factor-a cohort of cells reinitiates cell-cycle progression, entering S phase after a delay of -12 hr, corresponding to the G1 duration in cycling cells (refs. 8 and 19 , see also Fig. 5 ). The effects of these growth factors include rapid cyclin D1 induction (8) , and the data presented above (Fig. 4) suggest that this induction might lead to reentry into the cell cycle. Therefore, the possibility that cyclin D1 induction was sufficient to allow growth-arrested cells to progress through G1 and into S phase was examined. Serum-deprived T-47D AMTcycD1 cells displayed a higher S-phase fraction than parental or vectortransfected cells under the same conditions (Fig. SA) (19) , presumably as a result of constitutive expression from the metallothionein promoter (Figs. 1A and 5A ). However, insulin stimulation resulted in a similar degree of induction of endogenous cyclin D1 and a similar increase in the proportion ofcells entering S phase in T-47D AMTcycD1 and T47D AMT cells (Fig. 5) . Despite the absence ofexogenous growth factors, zinc induction of cyclin D1 in T-47D AMTcycDl cells arrested in early G1 phase resulted in a response similar to that observed in cycling cells-i.e., semisynchronous entry into S phase after -12 hr (Fig. 5) . Thus, induction of cyclin D1 was sufficient for completion of G1 phase and subsequent DNA synthesis. The rate of exit from G0 was slower and the proportion of cells reaching S phase was smaller in the presence of insulin than in the presence of zinc, as expected from the smaller relative induction ofcyclin D1 by insulin (Fig.   5 ). Only minor changes in either cycin D1 expression or cell-cycle progression were observed after zinc treatment of T-47D AMT cells when compared with the effects of zinc on T-47D AMTcycD1 (Fig. 5) . 
DISCUSSION
In cells that express cyclin D1, regulation of cyclin D1 gene expression is a common response to either stimulation or inhibition of cell-cycle progression (2, 6, 8, 17, 29, 30 epithelial origin (this study). Only two other mammalian genes have been shown to share this property: c-myc (33) and cyclin E (27) . Cyclin E appears to regulate progress through the restriction point just before the G1-S phase boundary (34) (35) (36) . Antibodies against cyclin D1 inhibit cell-cycle progression when microinjected during mid-GU phase but are ineffective near the G1-S boundary (28, 32) , showing that cyclin D1 acts earlier in G, than cyclin E. This result is consistent with the idea that the sequential activation of different cyclins reflects functions at consecutive control points during cell-cycle progression.
The proportion of breast cancer cells initiating progress through the cell cycle after induction of ectopic cyclin D1 expression depended on the cyclin D1 level. Similarly, in fibroblasts restimulated from quiescence by low serum concentrations, a much greater proportion of the population reentered the cell cycle in cell lines overexpressing cyclin D1 than in control cells (28 (30) . A likely explanation for the different effects of cyclin D1 induction is that breast cancer cells arrest near the beginning of G1 phase, rather than becoming truly quiescent upon serum deprivation (19) . In serum-deprived normal fibroblasts and mammary epithelium, cyclin D1 induction after mitogen stimulation is not apparent for 4-6 hr (6, 30) . This is a delayed response compared with the induction of cyclin D1 in serum-deprived breast cancer cells or colony-stimulating factor 1-deprived macrophages, both of which arrest in early G1 phase (2, 8) and suggests that cyclin D1 does not act during the initial stage of the transition from quiescence into DNA synthesis. Nevertheless, because cyclin D1 is sufficient for G1 transit, cyclin D1 overexpression might reduce the effects of physiological growth restraints, particularly in tumor cells that are already transformed. This hypothesis is supported by the observation that both rodent fibroblasts and human breast cancer cells overexpressing cyclin D1 maintain a higher S-phase fraction upon serum deprivation than control cells (ref. 28; this study).
A region of chromosome 11 encompassing the cyclin D1 gene is one of the most frequently amplified regions in human carcinomas (12, 13) . Amplification of 11q13 is associated with poor prognosis in breast cancer (37) (38) (39) , suggesting the presence of a gene contributing to tumor progression within the amplicon. Furthermore, cyclin D1 is the favored candidate oncogene activated by the t(11;14)(ql3;q32) translocation in a subset of B-cell lymphomas (11, 31) . Fibroblasts overexpressing cyclin D1 do not display features characteristic of transformation (28) . However, overexpression of cyclin D1 may contribute to the autonomous growth of a population of tumor cells, particularly in breast cancer, where the estrogen receptor-positive, hormone-responsive phenotype retains regulation of cell proliferation by steroids and growth factors (8, 18) . Furthermore, aberrant expression of cyclin D1 may result in resistance to some forms of therapy-e.g., endocrine therapy-because decreased expression of cyclin D1 is a likely mechanism contributing to growth inhibition by diverse agents, including antiestrogens (8) .
In summary, this study shows that regulation of cyclin D1 can change the rate of cell-cycle progression, thereby establishing a causal role for cyclin D1 in regulating proliferation in human epithelial cells and providing evidence that deregulation of this gene could contribute to loss of growth control in a range of human carcinomas, including breast cancer.
